ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Charlotte, NC, USA:

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Phase 3

Genelux

Charlotte, North Carolina, United States and 22 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 176 other locations

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Enrolling
Endometrial Cancer
Ovary Cancer
Drug: STRO-002

Phase 1

Sutro Biopharma

Charlotte, North Carolina, United States and 26 other locations

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Niraparib
Drug: Niraparib-Placebo

Phase 3

Tesaro
Tesaro

Charlotte, North Carolina, United States and 189 other locations

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,...

Active, not recruiting
Carcinoma, Ovarian Epithelial
Ovarian Cancer
Drug: Bevacizumab
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 186 other locations

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerab...

Enrolling
Breast Cancer
Ovarian Cancer
Drug: SON-DP

Phase 1

Qurgen Inc.

Huntersville, North Carolina, United States and 4 other locations

Dose (RP2D) in patients with ovarian cancer, and Part C will evaluate combination treatment of INX-315 plus a CDK4/6i and selectiv...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: INX-315

Phase 1, Phase 2

Incyclix Bio

Charlotte, North Carolina, United States and 6 other locations

This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and prel...

Enrolling
Solid Tumor
Drug: CPO-100

Phase 1

Conjupro Biotherapeutics

Huntersville, North Carolina, United States and 9 other locations

(with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzaluta...

Enrolling
Cancer of Ovary
Castration Resistant Prostatic Cancer
Drug: Olaparib
Drug: Enzalutamide

Phase 1, Phase 2

Nuvation Bio

Huntersville, North Carolina, United States and 31 other locations

, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian...

Enrolling
Epithelial Ovarian Cancer
Hepatocellular Cancer
Biological: vobramitamab duocarmazine
Biological: lorigerlimab

Phase 1

MacroGenics
MacroGenics

Huntersville, North Carolina, United States and 9 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems